On May 2, 2022, Dr. Gina M. Wallar, NeoGenomics, Inc.'s current President, Pharma Services Division, informed the Company of her intention to resign from her role effective May 27, 2022. In connection with Dr. Wallar's departure, Ms. Jennifer Rose will assume interim responsibility for the Pharma Services Division beginning on May 27, 2022. Ms. Rose joined the Company in December 2015 and currently serves as Vice President of Pharma Sales and Project Management Operations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.24 USD | +2.52% | -3.78% | -11.99% |
02/05 | North American Morning Briefing : Stock Futures -3- | DJ |
30/04 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.99% | 181.86Cr | |
-23.07% | 786.18Cr | |
+68.36% | 432.49Cr | |
+1.88% | 262.59Cr | |
-8.06% | 250.48Cr | |
-41.95% | 233.09Cr | |
-21.18% | 150.68Cr | |
+17.44% | 121.55Cr | |
-43.89% | 114.27Cr | |
+14.78% | 96Cr |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Announces Executive Changes